<p>Scatter plots between experimental versus predicted pIC50 values of wild types EGFR inhibitors.</p
<p>Weighted mean difference in eGFR (ml/min) in patients who received VDRAs compared with control th...
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdat...
<p>(A) Targeted inhibitors from the CCLE database. (B) Targeted inhibitors from the Sanger COSMIC da...
<p>Comparative performance of existing method with our method developing for predicting inhibitors a...
<p>List of descriptors showing positive and negative correlation with the wild EGFR inhibitory activ...
<p><b>and </b><b>.</b> Panel <b>A</b> shows separate scatterplots per inhibitor level whereas Panel ...
<p>Scatter plot showing the correlation between experimental and predicted pIC<sub>50</sub> values a...
<p>Two-way scatter graph for eGFR vs. 25OHD (A) or eGFR vs. 1,25OHD (B) in patients with type 2 diab...
<p>Scatterplots of fPAR and (a) fcoverintensity, and (b) CNRH from the 25 modeling plots.</p
<p>Scatter plots showing coefficient of correlation (r) between the experimental pIC<sub>50</sub>and...
<p>A scatter plot showing correlation between model-computed percentage steatosis for mouse biopsies...
<p>Forest plots of hazard ratios comparing progression-free survival of EGFRis with chemotherapy ver...
Representative 3 plots for each experimental condition are shown. A, ATP13A2-Halo-OregonG vs LysoTra...
<p>Forest plots depicting the effect of CETP inhibitors on apolipoproteins (grouped by different CET...
<p>Scatter plot of scores of PC2 vs. PC3 based on PCA of 13 size adjusted variables as described in ...
<p>Weighted mean difference in eGFR (ml/min) in patients who received VDRAs compared with control th...
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdat...
<p>(A) Targeted inhibitors from the CCLE database. (B) Targeted inhibitors from the Sanger COSMIC da...
<p>Comparative performance of existing method with our method developing for predicting inhibitors a...
<p>List of descriptors showing positive and negative correlation with the wild EGFR inhibitory activ...
<p><b>and </b><b>.</b> Panel <b>A</b> shows separate scatterplots per inhibitor level whereas Panel ...
<p>Scatter plot showing the correlation between experimental and predicted pIC<sub>50</sub> values a...
<p>Two-way scatter graph for eGFR vs. 25OHD (A) or eGFR vs. 1,25OHD (B) in patients with type 2 diab...
<p>Scatterplots of fPAR and (a) fcoverintensity, and (b) CNRH from the 25 modeling plots.</p
<p>Scatter plots showing coefficient of correlation (r) between the experimental pIC<sub>50</sub>and...
<p>A scatter plot showing correlation between model-computed percentage steatosis for mouse biopsies...
<p>Forest plots of hazard ratios comparing progression-free survival of EGFRis with chemotherapy ver...
Representative 3 plots for each experimental condition are shown. A, ATP13A2-Halo-OregonG vs LysoTra...
<p>Forest plots depicting the effect of CETP inhibitors on apolipoproteins (grouped by different CET...
<p>Scatter plot of scores of PC2 vs. PC3 based on PCA of 13 size adjusted variables as described in ...
<p>Weighted mean difference in eGFR (ml/min) in patients who received VDRAs compared with control th...
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdat...
<p>(A) Targeted inhibitors from the CCLE database. (B) Targeted inhibitors from the Sanger COSMIC da...
DOI
Add to ORKG